Cerus Strengthens European Management Team.William "Obi" Greenman Promoted to President, Cerus Europe CONCORD, Calif. -- Cerus Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CERS) announced today the promotion of William "Obi" Greenman to the newly created position of President, Cerus Europe, reporting to Claes Glassell, President and Chief Executive Officer. Currently, Mr. Greenman serves as Cerus' Vice-President, Business Development. Effective immediately, Mr. Greenman will be responsible for directing the European commercialization efforts for Cerus' lead product, the INTERCEPT Blood System. The INTERCEPT Blood System for platelets is currently on the market in Europe and the INTERCEPT Blood System for plasma is currently pending review for CE mark approval. "I am delighted that Obi has accepted this promotion," said Claes Glassell, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cerus. "We are encouraged by the progress of our commercialization of the INTERCEPT Blood System in Europe, and Obi will add to the existing breadth of leadership in our European headquarters." Mr. Greenman will be leading a strong executive team that includes Caspar Hogeboom, INTERCEPT Managing Director Cerus Europe and by Keith Henderson Keith Henderson (born August 4, 1966 in Cartersville, Georgia) is a former American football running back who played for the San Francisco 49ers and Minnesota Vikings of the National Football League. Henderson attended the University of Georgia. , Vice-President, Manufacturing and Operations, both of whom were appointed in March of 2006. Mr. Greenman has an extensive experience base at Cerus, having led business development, marketing and strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. activities for more than a decade. In his role as VP of Business Development, Mr. Greenman has been a key member of Cerus' management team. He led the restructuring of the company's relationship with Baxter International Baxter International Inc. (NYSE: BAX), is a global healthcare company with 48,000 employees and 2006 sales of US$10.4 billion. Its headquarters is in Deerfield, Illinois. , structured the relationships with both BioOne and MedImmune and was instrumental in establishing the Cerus European headquarters and staffing the European organization. Prior to joining Cerus in 1995, Mr. Greenman served in various corporate development and marketing capacities for the Baxter Biotech Group, the biotech division of Baxter International. Mr. Greenman holds degrees in Biological Sciences and Economics from Stanford University Stanford University, at Stanford, Calif.; coeducational; chartered 1885, opened 1891 as Leland Stanford Junior Univ. (still the legal name). The original campus was designed by Frederick Law Olmsted. David Starr Jordan was its first president. . ABOUT CERUS Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Attenuated Alive but weakened; an attenuated microorganism can no longer produce disease. Mentioned in: Tuberculin Skin Test attenuated having undergone a process of attenuation. Listeria Listeria /Lis·te·ria/ (lis-ter´e-ah) a genus of gram-negative bacteria (family Corynebacterium); L. monocyto´genes causes listeriosis. Lis·te·ri·a n. vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies . INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion